Financial Analysis: Senestech (SNES) & Medpace Holdings (MEDP)
Senestech (NASDAQ: SNES) and Medpace Holdings (NASDAQ:MEDP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.
This is a breakdown of recent recommendations and price targets for Senestech and Medpace Holdings, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Senestech presently has a consensus target price of $14.50, indicating a potential upside of 643.59%. Medpace Holdings has a consensus target price of $35.75, indicating a potential upside of 3.47%. Given Senestech’s stronger consensus rating and higher probable upside, equities analysts plainly believe Senestech is more favorable than Medpace Holdings.
Valuation & Earnings
This table compares Senestech and Medpace Holdings’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Medpace Holdings||$421.58 million||3.08||$13.42 million||$0.68||50.81|
Medpace Holdings has higher revenue and earnings than Senestech.
Institutional and Insider Ownership
20.2% of Senestech shares are held by institutional investors. Comparatively, 17.6% of Medpace Holdings shares are held by institutional investors. 27.4% of Senestech shares are held by insiders. Comparatively, 25.8% of Medpace Holdings shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Senestech and Medpace Holdings’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Senestech beats Medpace Holdings on 6 of the 11 factors compared between the two stocks.
Senestech Company Profile
SenesTech, Inc. is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes. Using bait stations, ContraPest is dispensed in a palatable liquid formulation that promotes sustained consumption by rodent communities. Its formulation causes both female and male rats to become infertile once they have consumed the dose. The active ingredient in females accelerates the rate at which ovarian follicles (egg structures) are depleted. Once these cells are gone, the animal cannot reproduce. In males, there is a marked reduction in the ability to fertilize eggs and, often complete sterility. ContraPest is designed, formulated and dispensed for handlers and non-target species, such as wildlife and pets in a biodegradable product.
Medpace Holdings Company Profile
Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Receive News & Stock Ratings for Senestech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senestech Inc. and related stocks with our FREE daily email newsletter.